NCT02268149已完成1 期
The Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Male Subjects (A Randomized, Double-blind, Placebo-controlled, Two Period, Two-way Cross-over Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 主要终点
- Cmax (Maximum measured concentration of the analyte in plasma)
研究概览
简要总结
Study to evaluate the effect of multiple doses of BIIL 284 BS on the pharmacokinetics of a single dose of prednisone
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Written informed consent signed and dated prior to participation into the study
- •All participants in the study should be healthy males, aged 18-50 years old inclusive
- •All participants should be within (+- 20%) of their ideal body weight (Broca-Index)
- •Non-smokers (subject who have never smoked) or ex-smoker for at least one year with a smoking history, no greater than five pack-years (1 pack year = 20 cigarettes per day for 1 year)
- •Ability to comply with the concomitant therapy restrictions as detailed in Clinical Trial Protocol (CTP)
- •Subjects will be off all prescription drugs. O.T.C. drugs must be discontinued for at least two weeks prior to participation in the study. If throughout the study, subjects need any O.T.C. medication, the investigator will call the clinical monitor and this will be reviewed on a case-by-case basis. Restrictions for different medications are described in CTP
- •Subjects will have no evidence of clinically relevant concomitant disease based upon complete medical history, full physical examination, chest-x-ray (if not done in previous 6 months), ECG and clinical laboratory tests
排除标准
- •Viral respiratory tract infection or a respiratory tract infection within the six weeks preceding dosing with study medication
- •Small or difficult to locate arm or hand veins that would impair the clinicians ability to draw blood samples or to place a venous catheter
- •Subjects with a known drug or alcohol dependence (absence of dependency for 10 years) or who drink more than 60 g of alcohol per day, history of significant allergic reactions to drugs or sensitivity to aspirin or positive drug screen
- •Use of investigational new drug in the preceding month or six half-lives (whichever is greater) prior to the first screen at Visit 1
- •Donation of blood during the month preceding Visit 1
- •Subjects receiving hyposensitization therapy who are not on a stable dose for the last three months before Visit 1
- •Subjects with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Subjects with diseases of the central nervous system (such as epilepsy) or with psychiatric disorders
- •Subjects with known history of orthostatic hypotension, fainting spells or blackouts
- •Subjects with chronic or relevant acute infections
- •Subjects with history of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Subjects with eosinophilia > 7 %
- •Subjects who received any other drugs, which might influence the results of the trial during the weeks prior to dosing with study medication
- •Subjects who participated in excessive physical activities (e.g. competitive sports) within the last week before dosing with study medication
研究组 & 干预措施
BIIL 284 BS + Prednisone
Experimental
BIIL 284 BS 9 days; prednisone 2 single doses
干预措施: BIIL 284 BS (Drug)
BIIL 284 BS + Prednisone
Experimental
BIIL 284 BS 9 days; prednisone 2 single doses
干预措施: Prednisone (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Cmax (Maximum measured concentration of the analyte in plasma)
时间窗: up to 72 hours post dose
tmax (Time from dosing to the maximum concentration of the analyte in plasma)
时间窗: up to 72 hours post dose
AUC (Area under the concentration-time curve of the analyte in plasma)
时间窗: up to 72 hours post dose
t½ (Terminal half-life of the analyte in plasma)
时间窗: up to 72 hours post dose
MRTtot (total Mean residence time)
时间窗: up to 72 hours post dose
Vz/F (Apparent volume of distribution of the analyte during the terminal phase)
时间窗: up to 72 hours post dose
CLtot/F (Total clearance of the analyte in plasma after oral administration)
时间窗: up to 72 hours post dose
次要结局
- Number of subjects with adverse events(up to 53 days)
- Changes in Interleukin-2 (IL-2) levels(predose, 4 hours post dose)
- Changes in immunomodulatory assessed by T-cell proliferation(predose, 4 hours post dose)
- Changes in Interferon gamma (IFNy) levels(predose, 4 hours post dose)
研究者
相似试验
已完成
1 期
Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male VolunteersHealthyNCT02273440Boehringer Ingelheim16
已完成
1 期
Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female VolunteersHIV InfectionsNCT01374802Boehringer Ingelheim14
已完成
1 期
A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the BloodHealthyNCT05613777Boehringer Ingelheim19
已完成
1 期
Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy VolunteersHepatic InsufficiencyNCT02265627Boehringer Ingelheim32
已完成
1 期
Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and DigoxinHealthyNCT02783040Boehringer Ingelheim13